Lantern Pharma is trading 5.7% down in pre-market at $2.50 as investors continued digesting its August 14 second-quarter earnings release, including a loss miss and funding warning.
- Reported a $7.1 million net loss, or $0.57 per share, missing the $0.38 estimate.
- Warned substantial additional funding is needed to continue operations; clinical progress and a 25% lower operating loss were positive.
- The broader market is modestly mixed-to-positive, while coverage described the stock slipping after the headline loss miss.